Respicardia said today it launched its Remedē transvenous implantable neurostimulation system designed to treat patients with central sleep apnea, and that it named Peter Sommerness as CEO.
The Remedē system consists of a surgically placed battery pack and thin wires inserted into the blood vessels in the chest near the phrenic nerve, which it stimulates to engage the diaphragm to restore natural breathing during sleep and improve patient quality of life and satisfaction.
“Central sleep apnea is very common in cardiac patients, especially patients with heart failure, and is associated with a significantly greater risk for morbidity and mortality. Being able to treat CSA offers a new hope to improve the quality of life for my patients,” Dr. William Abraham of the Ohio State University Wexner Medical Center said in prepared remarks.
The procedure treating the first patient was performed by Dr. Ralph Augostini at Columbus’ Ohio State University Wexner Medical Center, the Minnetonka, Minn.-based company said.
“The Remedē System is a breakthrough technology that uniquely treats central sleep apnea while greatly improving a patient’s quality of life. I am proud to be a part of the system’s first U.S. commercial case that has the potential to become the standard of care for these patients,” Dr. Augostini said in a prepared statement.
Prior to joining Respicardia, Sommerness served as a partner at McKinsey and Company, and has held the role of GM and cardiac electrophysiology VP at Boston Scientific, the company said.
“I’m excited to join Respicardia and its seasoned team at such a pivotal moment. With the major milestone of our first U.S. commercial implant, I look forward to building on this momentum in the U.S. market and to bringing this groundbreaking technology to patients suffering from the harmful effects of central sleep apnea,” Sommerness said in a press release.